Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03425799
Registration number
NCT03425799
Ethics application status
Date submitted
23/01/2018
Date registered
8/02/2018
Date last updated
21/06/2021
Titles & IDs
Public title
Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery
Query!
Scientific title
Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery
Query!
Secondary ID [1]
0
0
CP-006-2017
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Spinal Fusion
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Sodium Chloride 0.9% Inj
Treatment: Drugs - Tranexamic Acid
Placebo Comparator: Sodium Chloride 0.9% - Sodium Chloride 0.9% infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
Experimental: Tranexamic Acid 10 mg/mL - Tranexamic Acid 10 mg/mL infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
Treatment: Drugs: Sodium Chloride 0.9% Inj
Inactive ingredient mixture for injection without drug, intravenous infusion bags containing normal saline, manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
Treatment: Drugs: Tranexamic Acid
Tranexamic Acid Intravenous Infusion Bags (10 mg/mL), manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Total Blood Loss
Query!
Assessment method [1]
0
0
The Total Blood Loss will be estimated based on the hemoglobin content of the blood prior to surgery (mg/dL) and at each of the desired post-surgery time-points (mg/dL). Blood samples for hemoglobin measurement will be collected prior to start of procedure, at the end of the procedure, at 24 h, and every 24 h thereafter until discharge and removal two subfascial drains.
Query!
Timepoint [1]
0
0
From time of surgery until discharge
Query!
Primary outcome [2]
0
0
Incidence of Autologous or Allogenic Blood Transfusion
Query!
Assessment method [2]
0
0
Number of Units of autologous transfusion and allogenic transfusion
Query!
Timepoint [2]
0
0
From time of surgery until discharge
Query!
Secondary outcome [1]
0
0
Total Measured Blood Loss
Query!
Assessment method [1]
0
0
Estimated as 3x cell saver
Query!
Timepoint [1]
0
0
From time of surgery up to 24 hours after surgery
Query!
Secondary outcome [2]
0
0
Number of Patients With Symptomatic Anemia Precipitated Transfusion
Query!
Assessment method [2]
0
0
Number of patients with symptomatic anemia precipitated transfusion in each group
Query!
Timepoint [2]
0
0
Until discharge
Query!
Secondary outcome [3]
0
0
Number of Patients With Adverse Events Related to Tranexamic Acid
Query!
Assessment method [3]
0
0
Number of patients with adverse events related to tranexamic acid in each group
Query!
Timepoint [3]
0
0
up to 6 weeks
Query!
Eligibility
Key inclusion criteria
- All adult patients (Male or Female) over age eighteen (>18) electively undergoing
complex spinal fusion surgery (defined as T2 to Pelvis/Sacrum and greater than 4
Functional Spinal Units (4 discs/motion segments=5 Vertebral segments).
- Female subjects of childbearing potential with a negative serum (beta human chorionic
gonadotropin [HCG]) pregnancy test at screening and urine pregnancy test at each
admission; who are not breastfeeding; do not plan to become pregnant during the course
of the study; and agree to use an approved method of birth control, such as condoms,
foams, jellies, diaphragm, intrauterine device, sexual abstinence for at least 3
months prior to study
- Able to provide written informed consent after risks and benefits of the study have
been explained
- Able to communicate effectively with study personnel.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- History or presence of any clinically significant (based on the Investigator's
judgment) cardiovascular, respiratory, metabolic, hepatic, gastrointestinal, renal,
hematological, dermatological, neurological, or psychiatric disease or condition
preventing the use of tranexamic acid
- History of renal failure or elevated creatinine above 1.4
- Any diagnosis of spinal tumor or intradural pathology
- Diagnosis of ankylosing spondylitis
- History or presence of acquired disturbance of color vision
- History of seizures
- History of thromboembolic event (DVT or PE) within the past year
- Current use of anticoagulant medications or past medical history leading to an
abnormal coagulation profile preoperatively
- Subjects diagnosed with fibrinolytic disorders requiring intra-operative
antifibrinolytic treatment; hematological disease (thromboembolic events,
hemoglobinopathy, coagulopathy, or hemolytic disease)
- Significant drug sensitivity or significant allergic reaction to any drug, including
tranexamic acid, based on the Investigator's judgment
- A subject who has donated or lost 450 mL or more blood volume (including
plasmaphoresis) or had a transfusion of any product within 3 months prior to the
initial study drug administration
- Pre-operative anemia (hb <110 in females, Hb <120 in males)
- Any subject that chooses to refuse blood products for ethical or religious purposes
(Jehovah's Witness)
- Current participation in a drug or other investigational research study or
participation within 30 days prior to the initial study drug administration
- A subject who may not be able to comply with the safety monitoring requirements of
this clinical trial or is considered by the investigator, for any reason, to be an
unsuitable candidate for the study.
- Intraoperative cardiovascular, pulmonary, orthopedic, or anesthetic complication such
as myocardial infarction, intraoperative fracture, vasopressor support or emergent
intubation.
- Female patients who are using combination hormonal contraception.
- Patients with history of subarachnoid hemorrhage.
- Patients with serum creatinine above upper limit of normal (ULN).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
17/10/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
21/01/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
5
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Illinois
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
New York
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Exela Pharma Sciences, LLC.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to see if Tranexamic Acid can safely reduce bleeding in people
undergoing spinal fusion surgery.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03425799
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Neel Anand, MD
Query!
Address
0
0
Cedars-Sinai Medical Center
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03425799
Download to PDF